Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
Chief Executive Officer, Spyre Therapeutics
Search every verified Cameron Turtle interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Cameron Turtle, chief executive officer of Waltham, Massachusetts-based Spyre Therapeutics, discussed the company’s work on developing long-lasting antibody drug candidates for immune disorders in a September 2026 podcast appearance. He described the company’s approach as engineering antibodies to remain stable in the bloodstream longer than current drugs, potentially reducing injection frequency and enabling combination therapies that could improve efficacy while maintaining a straightforward treatment regimen. Spyre was spun out in 2023 from antibody discovery firm Paragon Therapeutics, which was founded by Fairmont Funds, and its portfolio includes antibodies targeting alpha 4 beta 7, TL1A, and the P19 subunit of IL23. During the interview, Turtle also commented on the pharmaceutical industry’s public perception, stating that the industry does not do a good job of communicating its contributions. He noted that while new drugs are costly at initial approval, their benefits persist at relatively low cost once they go off patent, and he expressed a view that the industry should improve how it presents this long-term value.
Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.
Cameron Turtle is the CEO of Spyre Therapeutics. His team is developing a new class of therapies for ulcerative colitis and Crohn's disease that are more effective and convenient for patients. Expect to learn what life is like at a hyper-competitive consulting company, the skills needed to work at a start-up, and the steepest parts of the learning curve for a new CEO. Cameron: / cameron-turtle-701b3533 Spyre Therapeutics: https://spyre.com/ Sponsors: Sage Bionetworks - driving a new age of discovery through open science and radical collaboration https://sagebionetworks.org/ Get in to…
Spyre (SYRE) is a biotech company that aims to create the next-generation of inflammatory bowel disease products. CEO Cameron Tuttle joins Oliver Renick to discuss the company as it began trading on the NASDAQ following an acquisition of Aeglea. Tuttle talks about how the IBD market is expected to grow to $29B by 2028, as the CDC estimates that 3.1M Americans have been diagnosed with IBD. Tune in to find out more about the stock market today. #investing #trading #finance #stocks #global #equities #markets #stockmarket #stockmarkettoday #spyre #syre
Sign in to search the full transcript archive, filter by topic, and access every quote from Cameron Turtle.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans